Clinical Specialties Compounding Pharmacy Recalls Hydroxyprogesterone Due to Sterility Concerns
Clinical Specialties Compounding Pharmacy is recalling Hydroxyprogesterone 250 mg/ml because FDA inspections raised concerns about quality control and sterility assurance.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric for drug recalls involving potential health risks.
Plain-English summary
Clinical Specialties Compounding Pharmacy is recalling specific lots of Hydroxyprogesterone 250 mg/ml. The recall was initiated following FDA inspection findings that resulted in concerns regarding the quality control processes used to ensure the sterility of the product.
The affected product was distributed in Florida, Georgia, and South Carolina. The specific lots subject to the recall include Lot number CABDAIAB:64 (Exp date: 4/8/2013), Lot number CABDAEAB:21 (Exp date: 4/4/2013), Lot number CABDBIAB:75 (Exp date: 4/18/2013), Lot number CABDAEAC:00 (Exp date: 5/5/2013), and Lot number CABDJAC:67 (Exp date: 5/20/2013).
Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If you have this product, you should stop using it and contact the recalling firm or your healthcare provider for further instructions.
The recalled product
- Product
- Hydroxyprogesterone 250 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907
- Manufacturer
- Clinical Specialties Compounding Pharmacy
- Category
- Drug — Compounded Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot number CABDAIAB:64
- Exp date: 4/8/2013
- Lot number CABDAEAB:21
- Exp date: 4/4/2013
- Lot number CABDBIAB:75
- Exp date: 4/18/2013
- Lot number CABDAEAC:00
- Exp date: 5/5/2013 and Lot number CABDJAC:67
- Exp date: 5/20/2013.
Distribution
Part of a larger recall action
This product is one of 49 recalled by Clinical Specialties Compounding Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 49 products in this recall →Related recalls
Same manufacturer · Clinical Specialties Compounding Pharmacy
See all →- SevereAvastin Syringes Recalled for Sterility Concerns and Eye Infection Reports
FDA (Drugs) · 2013-09-04
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 250 mg-lidocaine 5 mg/ml
FDA (Drugs) · 2013-07-10
- SevereEstradiol Cypionate Injection Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 200 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 100 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29